
US-based Affymax, Inc. develops peptide-based drugs for cancer and kidney disease treatment.
Affymax, Inc., founded in Cupertino, United States, is a clinical-stage biopharmaceutical company dedicated to developing peptide-based drugs for the treatment of cancer and kidney disease. The company's core mission is to improve patient outcomes and enhance the quality of life for individuals suffering from these severe conditions. Affymax focuses on innovative therapeutic solutions that address unmet medical needs in the healthcare sector.
Notable figures associated with Affymax include experienced professionals in biopharmaceutical research and development. The company has garnered attention from key investors in the healthcare industry, contributing to its growth and research capabilities. Affymax's significant achievements include advancing several promising drug candidates through clinical trials, potentially offering new treatment options for patients with cancer and kidney disease. The overall impact of Affymax's work lies in its potential to revolutionize treatment protocols and improve patient care in these critical areas.

Affigen
affigen.com

AffaMed Therapeutics
affamed.com

AimMax Therapeutics
aimmaxrx.com

Apexian Pharmaceuticals
apexianpharma.com

Peak Bio
peak-bio.com

Endevica Bio
endevicabio.com

MacroGenics
macrogenics.com

Kyntra Bio
fibrogen.com
Altiris Therapeutics

AmideBio
amidebio.com

Permeon Biologics
permeonbio.com

Afraxis

AsclepiX Therapeutics
asclepix.com

NantBio

Novita Pharmaceuticals
novita-pharm.com
Companies similar to Affymax include Affigen, AffaMed Therapeutics, AimMax Therapeutics and Apexian Pharmaceuticals.
Affymax was founded in 2001.
Affymax's headquarters is located in Cupertino, CA, US.
As of Jun 6, 2013, Affymax has raised a total of $173M (USD).